Con­tin­u­ing an R&D re­vamp, Glax­o­SmithK­line hands off its rare dis­ease unit to Or­chard Ther­a­peu­tics

Glax­o­SmithK­line couldn’t find a buy­er for their gene ther­a­py unit, but they did find a tak­er.

An­drea Spezzi

GSK said this morn­ing that it has lat­eraled off the group to a ven­ture-backed start­up called Or­chard Ther­a­peu­tics, which in­cludes co-founder An­drea Spezzi in a group of ex-GSK staffers with close ties to Strimvelis, a pi­o­neer­ing gene ther­a­py that was a key part of this deal. Af­ter shop­ping the deal for months, the GSK team end­ed up vir­tu­al­ly giv­ing it away in ex­change large­ly for a chunk of eq­ui­ty — un­der­scor­ing their in­abil­i­ty to cre­ate much val­ue in the ef­fort.

The deal al­so in­cludes un­spec­i­fied roy­al­ties and mile­stones.

Em­ma Walm­s­ley made it clear back in Ju­ly that the rare dis­ease unit at Glax­o­SmithK­line was on the auc­tion block. The move was part of their plan to stream­line the pipeline, shed­ding mar­gin­al or worth­less as­sets and re­fo­cus­ing on key dis­eases while ex­pand­ing their base in on­col­o­gy R&D.

Em­ma Walm­s­ley

Or­chard will now have own­er­ship of Strimvelis, the ex vi­vo gene ther­a­py for “bub­ble boy syn­drome.” Al­so in the deal bas­ket are two late-stage clin­i­cal pro­grams for metachro­mat­ic leukody­s­tro­phy (MLD) and Wiskott Aldrich syn­drome (WAS), one clin­i­cal pro­gramme for be­ta tha­lassemia, and rights to three pre­clin­i­cal pro­grams. In ex­change, GSK is tak­ing a 19.9% stake and a board seat in the UK biotech.

Al­though Strimvelis was ap­proved in Eu­rope in 2016, GSK has strug­gled to find cus­tomers among the ex­treme­ly small group of chil­dren with what is of­fi­cial­ly called adeno­sine deam­i­nase se­vere com­bined im­mun­od­e­fi­cien­cy, even af­ter of­fer­ing a mon­ey-back guar­an­tee. Lim­it­ed pa­tient ac­cess was a short­com­ing for Strimvelis — pa­tients could on­ly be treat­ed in a sin­gle cen­ter in Mi­lan, with just 15 cas­es di­ag­nosed in Eu­rope each year.

Mark Rothera

Or­chard be­lieves their ex­per­tise in cry­op­reser­va­tion would al­low Strimvelis to over­come that bar­ri­er and be shipped across the world in a frozen state. CEO Mark Rothera told Bloomberg last month that in de­vel­oped na­tions world­wide, up to 200 ba­bies are born with the im­mun­od­e­fi­cien­cy.

Bag­ging these as­sets, es­pe­cial­ly a com­mer­cial prod­uct, is sig­nif­i­cant for Or­chard, a young biotech that has nonethe­less se­cured $140 mil­lion for its gene ther­a­pies. Fol­low­ing the an­nounce­ment of the deal, Rothera spread the word that his team is look­ing to raise more cap­i­tal through a pri­vate sale of its shares. Be­yond that, the pipeline ex­pan­sion may al­so lead to an IPO.

“The ad­di­tion of these pro­grams is a re­al­ly big step up in terms of ac­tiv­i­ty, so we are go­ing to be look­ing to raise fur­ther funds through an ad­di­tion­al pri­vate round,” Rothera told Reuters. “From an in­vestor com­mu­ni­ty point of view there is a huge amount of in­ter­est and will­ing­ness to sup­port de­vel­op­ment of these med­i­cines. I am very con­fi­dent that we will be rais­ing funds in the not too dis­tant fu­ture.”

John Lep­ore

The agree­ment marks the close of a chap­ter in GSK’s re­or­ga­ni­za­tion sto­ry, out­lined to fo­cus on res­pi­ra­to­ry and HIV/in­fec­tious dis­eases, which the UK phar­ma gi­ant al­ready has a foot in, as well as on­col­o­gy and im­muno-in­flam­ma­tion — ar­eas new R&D chief Hal Bar­ron is now ex­plor­ing.

“Since we an­nounced our in­tent to re­view these med­i­cines, our goal has been to iden­ti­fy the right own­er who can build on what we’ve al­ready achieved, and can ad­vance these im­por­tant med­i­cines for pa­tients, al­low­ing GSK to fo­cus on build­ing its broad­er cell and gene ther­a­py plat­form ca­pa­bil­i­ties,” said John Lep­ore, GSK’s se­nior vice pres­i­dent, R&D pipeline, in a state­ment.

And they think Or­chard is the right part­ner. The duo will share some re­spon­si­bil­i­ties dur­ing the tran­si­tion pe­ri­od, which lasts un­til the end of 2018.

With ad­di­tion­al re­port­ing by John Car­roll.

Regeneron CEO Leonard Schleifer speaks at a meeting with President Donald Trump, members of the Coronavirus Task Force, and pharmaceutical executives in the Cabinet Room of the White House (AP Photo/Andrew Harnik)

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

The US government is on a spending spree. And after committing billions to vaccines defense operations are now doling out more of the big bucks through Operation Warp Speed to back a rapid flip of a drug into the market to stop Covid-19 from ravaging patients — possibly inside of 2 months.

The beneficiary this morning is Regeneron, the big biotech engaged in a frenzied race to develop an antibody cocktail called REGN-COV2 that just started a late-stage program to prove its worth in fighting the virus. BARDA and the Department of Defense are awarding Regeneron a $450 million contract to cover bulk delivery of the cocktail starting as early as late summer, with money added for fill/finish and storage activities.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Andrew Kruegel, Kures president and co-founder (Columbia Tech Ventures via Vimeo)

Af­ter psilo­cy­bin and ke­t­a­mine, a new biotech comes along de­vel­op­ing a drug Scott Got­tlieb fought

Andrew Kruegel was six years into his chemistry work at Columbia University, when, one day in August 2016, he learned he might have only 30 days before the government made him destroy his research.

Kruegel had been studying kratom, a leaf long used in Southeast Asia as a stimulant or for pain. It had opioid-like properties, he found, but seemed to offer pain relief without the addictive potential or respiratory side effects of traditional opioids — a riddle that might help illuminate how human opioid receptors work.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

The home run count: The $100M+ mega-round boom in biotech in­spired a $7.3B feed­ing fren­zy — so far this year

Over the last 6 months there’s been a blizzard of money piling up drifts of the green stuff through the biotech landscape. And the forecast calls for more cash windfalls ahead.

Even as a global pandemic has killed more than half a million people, blighted economies and divided nations over the proper response, it’s also helped ignite an unprecedented burst of big-time investing. And not just in Covid-19 deals, as we’ve looked at before.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

UP­DAT­ED: Bio­gen shares spike as ex­ecs com­plete a de­layed pitch for their con­tro­ver­sial Alzheimer's drug — the next move be­longs to the FDA

Biogen is stepping out onto the high wire today, reporting that the team working on the controversial Alzheimer’s drug aducanumab has now completed their submission to the FDA. And they want the agency to bless it with a priority review that would cut the agency’s decision-making time to a mere 6 months.

The news drove a 10% spike in Biogen’s stock $BIIB ahead of the bell.

Part of that spike can be attributed to a relief rally. Biogen execs rattled backers and a host of analysts earlier in the year when they unexpectedly delayed their filing to the third quarter. That delay provoked all manner of speculation after CEO Michel Vounatsos and R&D chief Al Sandrock failed to persuade influential observers that the pandemic and other factors had slowed the timeline for filing. Actually making the pitch at least satisfies skeptics that the FDA was not likely pushing back as Biogen was pushing in. From the start, Biogen execs claimed that they were doing everything in cooperation with the FDA, saying that regulators had signaled their interest in reviewing the submission.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Atul Deshpande, Harbour BioMed chief strategy officer & head, US operations (Harbour BioMed)

An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

A short four months after announcing a $75 million haul in Series B+ fundraising, the multinational biotech Harbour BioMed pulled in another round of investments and eclipsed the nine-digit mark in the process.

Harbour completed its Series C financing, the company announced Thursday morning, raising $102.8 million and bringing its total investment sum to over $300 million since its founding in late 2016. The biotech plans to use the money to transition early-stage candidates from the discovery phase, fund candidates already in the clinic, and prep late-stage candidates for commercialization.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Daniel O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)

A new study points to $6.5B in pub­lic sup­port build­ing the sci­en­tif­ic foun­da­tion of Gilead­'s remde­sivir. Should that be re­flect­ed in the price?

By drug R&D standards, Gilead’s move to repurpose remdesivir for Covid-19 and grab an emergency use authorization was a remarkably easy, low-cost layup that required modest efficacy and a clean safety profile from just a small group of patients.

The drug OK also arrived after Gilead had paid much of the freight on getting it positioned to move fast.

In a study by Fred Ledley, director of the Center for Integration of Science and Industry at Bentley University in Waltham, MA, researchers concluded that the NIH had invested only $46.5 million in the research devoted to the drug ahead of the pandemic, a small sum compared to the more than $1 billion Gilead expected to spend getting it out this year, all on top of what it had already cost in R&D expenses.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

For­bion spot­lights late-stage plays, carves out new €250M growth fund

Having staked its rep on picking out a mix of biotech investment opportunities across the “build,” “enable,” “growth” continuum, Forbion is launching its first fund dedicated to late-stage opportunities.

Forbion Growth Opportunities Fund’s first close brought in €185 million ($208 million). Existing investors Pantheon, KfW Capital and the European Investment Fund came on board, joined by new backers Eli Lilly, Horizon Therapeutics, Belgian Growth Fund and New Waves Investments.

Ed Engleman (Stanford Blood Center)

Stan­ford star on­col­o­gy sci­en­tist Ed En­gle­man helped cre­ate the im­munother­a­py field. Now he wants to shake up neu­rode­gen­er­a­tion R&D

Over the last generation of drug R&D, Ed Engleman has been a standout scientist.

The Stanford professor co-founded Dendreon and provided the scientific insights needed to develop Provenge into a pioneering — though not particularly marketable — immunotherapy. He’s spurred a slate of startups, assisted by his well-connected perch as a co-founder of Vivo Capital, and took the dendritic cell story into its next chapter at a startup called Bolt.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.

Nello Mainolfi (Kymera via YouTube)

Out to re­vive R&D, a resur­gent Sanofi pays $150M cash to part­ner up with a pi­o­neer­ing pro­tein degra­da­tion play­er

Frank Nestle was appointed Sanofi’s global head of immunology and inflammation research therapeutic area just days before dupilumab, the blockbuster-to-be IL-4 antibody, would be accepted for priority review. After four years of consolidating immunology expertise from multiple corners of the Sanofi family and recruiting new talents to build the discovery engine, he’s set eyes on a Phase I-ready program that he believes can grow into a Dupixent-sized franchise.